Drugging histone methyltransferases in cancer
Current Opinion in Chemical Biology, ISSN: 1367-5931, Vol: 56, Page: 51-62
2020
- 40Citations
- 40Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations40
- Citation Indexes39
- 39
- CrossRef31
- Patent Family Citations1
- Patent Families1
- Captures40
- Readers40
- 40
Review Description
Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases — mainly EZH2 — is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in the field of histone methyltransferase inhibitors and describing the challenges that need to be addressed for their successful implementation in the clinics.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1367593119301309; http://dx.doi.org/10.1016/j.cbpa.2019.11.009; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85078555167&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/31981999; https://linkinghub.elsevier.com/retrieve/pii/S1367593119301309; https://dx.doi.org/10.1016/j.cbpa.2019.11.009
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know